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Background: The efficacy of artemisinin-based combination therapy (ACT) has been established. The objective of the
present study was to compare the efficacy and safety in the Central African Republic (CAR) of three commercially available
artemisinin-based combinations, artemether + lumefantrine (AL), artesunate + sulphamethoxypyrazine–pyrimethamine
(AS-SMP) and artesunate + amodiaquine (AS-AQ), with those of sulphadoxine–pyrimethamine + amodiaquine (SP-AQ),
which was the first-line reference treatment in the country from 2004, until it was replaced by ACT in 2006 in accordance
with changes in international recommendations based on resistance identified in other regions .
Methods: Children aged six to 59 months with uncomplicated Plasmodium falciparum malaria were recruited in Bangui,
the capital of the CAR. The 251 patients selected were randomly assigned to receive AL (n = 60), AS-SMP (n = 58), AS-AQ
(n = 68) or SP-AQ (n = 65) and were followed up for 28 days. Clinical outcome was classified according to the standard
2003 World Health Organization protocol.
Results: At day 28, the cure rates in a per-protocol analysis were 92% (48/52) with AL, 93% (50/54) with AS-SMP,
93% (55/59) with AS-AQ and 100% (57/57) with SP-AQ, with no statistically significant difference between the
four treatments. Defervescence was significantly faster with AS-AQ than with AL (p <0.035). Fatigue was reported
significantly more frequently by patients receiving AQ than by those treated with AS-SMP or AL (p = 0.006).
All the other adverse events reported were mild, and no significant difference was noted by treatment.
Conclusion: The three artemisinin-bsed combinations show similar, satisfactory results, comparable to that with
SP-AQ. This evaluation is the first conducted in CAR since the official introduction of ACT. It should guide the
National Malaria Control Programme in choosing the appropriate ACT for treatment of uncomplicated P. falciparum
malaria in the future.
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Malaria remains an important killer, particularly among chil-
dren in sub-Saharan Africa [1]; it also slows the develop-
ment of children and national economies [2]. Effective drugs
and adequate treatment compliance therefore play a key role
in lowering the malaria burden. As recommended by the
World Health Organization (WHO) [3], artemisinin-based
combination therapy (ACT) has become the reference treat-
ment for uncomplicated malaria in most endemic areas
[4-6]. Although resistance to artemisinin was recently ob-
served in western Cambodia [7,8], ACT has been found to
be effective all over the world, generally with good clinical
and parasitological responses [1,9-12]. Nevertheless, side ef-
fects, ease of administration, cost and duration of treatment
are important considerations in selecting anti-malarial
treatment.
In the Central African Republic (CAR), a high preva-
lence of chloroquine-resistant Plasmodium falciparum
necessitated a switch to sulphadoxine–pyrimethamine +
amodiaquine (SP-AQ) as the recommended first-line
treatment for uncomplicated P. falciparum malaria in
2004 [13,14]. In line with WHO recommendations, SP-
AQ was replaced by ACT in 2006 [15]. Unfortunately,
ACT was still not available in a number of health facilities
in 2006 [16], and chloroquine and SP remained in
common use at least until 2009 (personal observation),
despite a high prevalence of resistance to these drugs in
P. falciparum [17]. Medical doctors and nurses lacked
confidence in the efficacy of ACT, as some patients
returned with positive thick smears more than 72 hours
after treatment with artemether + lumefantrine (AL);
therefore, they continued to prescribe anti-malarial drugs
that were not recommended (personal observation). These
treatment failures may have been due to lack of communi-
cation or non-respect of the recommendation that this
drug be taken during a fatty meal to ensure good bio-
availability of artemether [18,19].
Only two clinical evaluations of anti-malarials have
been conducted in the CAR, besides efficacy studies of
chloroquine, AQ and various combinations with SP [13]
and an evaluation of artemether as mono-treatment for
P. falciparum malaria, which is no longer recommended
[20]. Thus, the switch to ACT in 2006 was based only
on the WHO recommendation and on clinical studies in
other African countries.
The objective of the present study was to assess the
efficacy and the safety of three artemisinin-based combi-
nations AL, artesunate (AS) + sulphamethoxypyrazine-
pyrimethamine (SMP) (AS + SMP is not a combination
recommended by WHO but is available on Central African
markets and is widely used) and AS + AQ in the CAR and
to compare their efficacy with that of the SP + AQ com-
bination that was previously used as first-line treatment in
the country.Methods
The study was carried out between May 2008 and May
2009 in two selected urban health centres, the Paediatric
Complex and the Saint Joseph, Health Centre, in Bangui,
the capital of the CAR, which draw children from all
districts of the city. Bangui is located on the Oubangui
River in the south of CAR, north of the Democratic
Republic of the Congo (geographical coordinates, 4.29 N,
18.35 E). The climate is tropical, and the rainy season
lasts from April to November. The temperature varies
from 19 to 32°C, with an average of 26°C. Malaria trans-
mission occurs throughout the year, with peaks at the
beginning and end of the rainy season. Malaria is hy-
perendemic, and the predominant parasite species is
P. falciparum.Study design
The study was a prospective randomized open-label trial
of the in vivo efficacy and safety of AL, AS-SMP and
AS-AQ in comparison with SP-AQ. Patients were followed
up for 28 days after treatment, with a clinical examination
and laboratory analysis. The study was carried out accor-
ding to the recommendations of WHO for surveillance of
the efficacy of anti-malarial drugs [21].Patients
Between May 2008 and May 2009, febrile patients aged
six to 59 months presenting to the two health facilities
were enrolled in the study if informed consent was pro-
vided by a parent or guardian and if they had an axillary
temperature ≥ 37.5°C or a history of fever in the preced-
ing 24 hours, a P. falciparum monoinfection, parasit-
aemia of 2,000–200,000 asexual parasites per μl of
blood, no known intolerance (e g, allergy) to the study
drugs, no use of any component of the study drugs
within the 28 days before enrolment, no cause of fever
other than malaria and no danger signs (unable to sit or
stand, unable to drink or breastfeed, lethargic or uncon-
scious, recent history of convulsions, persistent vomit-
ing) related or not to severe and complicated falciparum
malaria, according to the WHO definition [22]. To be
included, participants had to be able to come to the
health facility for follow-up. Parents or guardians were
asked by a physician about symptoms, duration of ill-
ness, previous anti-malarial therapy and other medica-
tions. Children were examined for pallor, jaundice and
any other danger sign, and their axillary temperature
and weight were measured.
Randomized codes, computer-generated by a third
party not involved in the study, were attributed to pa-
tients in numerical sequence by the investigators, per-
mitting their randomized allocation to one of the four
treatment groups.
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All drugs were from manufacturers that comply with
good manufacturing practice. AL (Coartem®) was pro-
vided by Novartis, Switzerland, AS-SMP (Coarinate®) by
DafraPharma, Belgium, AS-AQ (Coarsucam®) by Sanofi
Aventis, France, and SP (Fansidar®)–AQ by IDA, Netherlands.
Group 1 received AL, which is a combination of
20 mg artemether and 120 mg lumefantrine per tablet.
AL was administered according to body weight (5–14 kg,
one tablet; 15–24 kg, two tablets; 25–34 kg, three tab-
lets; ≥ 35 kg, four tablets) in six consecutive doses: the
first dose at diagnosis (day 0), the second eight hours
later (day 0) and then four doses at 12-hour intervals
over the following two days (days 1 and 2). The second
dose on day 0 was administered at home by study staff.
Group 2 received AS-SMP, which is available as “junior”
and infant treatment packs consisting of three tablets of
AS and three of SMP, each of which is given at the same
time. The junior tablets contain 100 mg AS and 250 mg
SMP with 12.5 mg of pyrimethamine, and the infant tab-
lets contain 50 mg AS and 125 mg SMP with 6.25 mg
pyrimethamine. The packs were prescribed according to
weight: children weighing 20–40 kg were given junior tab-
lets, those weighing 13–20 kg received one and a half in-
fant tablets, and those weighing 5–8 kg received one
infant tablet. The treatment consisted of three doses at
24-hour intervals (0 hours, 24 hours, 48 hours).
Group 3 received AS-AQ, which is presented in three
dosages per tablet: for large children (weighing 18–36 kg),
100 mg AS and 270 mg AQ; for small children (weighing
9–18 kg), 50 mg AS and 135 mg AQ; and for infants
(weighing 4.5-9 kg), 25 mg AS and 67.5 mg AQ. Treat-
ment consists of three tablets, taken one at a time at
24-hour intervals (0 hours, 24 hours, 48 hours).
Group 4 received SP-AQ, which exists in only one version,
with two tablets, one containing 500 mg sulphadoxine and
25 mg pyrimethamine and one containing 200 mg AQ hydro-
chloride. The dosage was determined by weight: children
weighing ≤10 kg received half a tablet, those weighing 10–
20 kg received one tablet, those weighing 21–30 kg were given
one and a half tablets, and those weighing 31–40 kg received
two tablets in one dose. The dose of AQ was 8 mg/kg per day
over three days given as single doses at 24-hour intervals.
Unless otherwise indicated, all drug doses were adminis-
tered at the health centre by the study team, with the ex-
ception of the second dose of AL, which was administered
in the patient’s home by the study team. For all groups, a
full dose was re-administered if the patient either spat out
the drug or vomited it within 30 min; half the dose was re-
administered if the patient vomited between 30 min and
one hour after administration. If the patient vomited again,
he or she was given another anti-malarial drug approved
by the National Malaria Control Programme and was then
excluded from the study.Treatment complement to improve absorption
To facilitate intestinal absorption of AL, lipid-rich food
in the form of sweetened milk concentrate was given to
young children (six to 36 months) and groundnut paste
to older children (37–59 months) [18,19,23,24].
Clinical follow-up
Patients were required to come to the health clinic on
days 0, 1, 2, 3, 7, 14, 21 and 28 for examination and at
any time they felt unwell. Venous blood was collected
on day 0, and blood from a finger prick was obtained on
each day of follow-up to prepare thin and thick smears
for microscopy and a filter paper blood spot for DNA
analysis. The patients or guardians were asked about
drug consumption since the last clinic visit. Individuals
for whom treatment failed were treated according to the
National Malaria Control Programme guidelines.
Microscopy
After thin films were fixed with methanol, both thin and
thick smears were stained with 4% Giemsa for 20 min.
The smears were read at the enrolment site, and all
slides were re-read by another technician who was un-
aware of the results of the previous analysis at the Insti-
tut Pasteur de Bangui. In case of a discrepancy, a third
reading was done, and the result agreed by at least two
technicians was considered for the analysis. A minimum
of 100 microscopic fields were examined, and parasite
density was calculated by counting the number of asex-
ual parasites per 200 white blood cells and adjusting for
the total white blood cell count by the standard approxi-
mation method (40 × number of parasites per 200 white
blood cells on a thick film). Thin blood smears were also
examined to determine the Plasmodium species.
Differentiation of persistence of infection and reinfection
To identify treatment failures correctly, a clear distinc-
tion had to be made between reinfection and recrudes-
cence for patients with recurrent parasitaemia after day
7. P. falciparum parasites present in blood samples col-
lected during the trial (on day 0 and the day of parasi-
taemia recurrence) were genotyped by polymerase chain
reaction (PCR) for the parasite merozoite surface protein
genes msp1 and msp2 and the glutamate-rich protein
(glurp) [25]. The alleles of the parasites present in the
two samples were compared to differentiate persistence
of infection (i.e. recrudescence when the alleles of each
gene were identical) from re-infection (i.e. different
alleles in at least one genes). The latter was not con-
sidered to represent failure.
Determination of transaminases
The levels of alanine and aspartate aminotransferase were
measured with an ABX Pentra 400 reader, according to
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from patients treated with combination treatments contai-
ning AQ (AS-AQ and SP-AQ) obtained on days 0, 1 and 3.
Study outcomes
The therapeutic outcome was classified on day 28 accord-
ing to the WHO protocol [21]. The primary end-point was
the 28-day cure rate, defined as the proportion of patients
with an adequate clinical and PCR-corrected parasitological
response. Secondary end-points were early treatment fail-
ure, late clinical failure, late parasitological failure, adverse
events, anaemia (haemoglobin <10 g/dl) and rates of clear-
ance of fever and parasitaemia and gametocyte carriage.
Parasite and fever clearances were assessed on days 1, 2
and 3, while gametocyte carriage was assessed on days 0, 3,
7, 14, 21 and 28. An adverse event was defined as a symp-
tom or an abnormal laboratory value not present on day 0
but occurring during follow-up, or present on day 0 but be-
coming worse during follow-up. Serious adverse events
were defined according to the WHO [26].
Statistical analysis
To demonstrate significant superiority (unilateral two-
group Fisher exact test) of any of the artemisinin-based
combinations over the SP-AQ regimen at risk p = 0.05, 57
individuals per treatment group would give a power of 99,
90 and 73% if the clinical and parasitological response rate
was 80% in the SP-AQ group and 100, 97.5 and 95% in the
three ACT groups. Moreover, if the observed clinical and
parasitological response rate was 100%, the lower limit of
the exact 95% confidence interval (CI) would be 94%. As-
suming a 10% non-accessibility rate (e.g. lost to follow-up),
we planned to enrol 251 children (about 63 per treatment
group). Data from the two study sites were pooled.
The intention-to-treat population analysis comprised all
randomized individuals. Children lost to follow-up and who
withdrew were considered possible treatment failures. The
per-protocol population analysis comprised all children who






















Figure 1 Trial design.time of treatment failure or the end of the study (28 days).
Children lost to follow-up or who withdrew, including those
who violated the protocol, were excluded from the per-
protocol analysis. The primary analysis was based on the
28-day PCR-corrected efficacy in both intention-to-treat
and per-protocol populations. Baseline and safety analyses
were done for the intention-to-treat population.
Data were double-entered, validated with Microsoft Access
and analysed with STATA version 10.0 (StataCorp College
Station, Texas 77845, USA). Chi-squared and Fisher exact
tests were used to compare categorical variables. A Kruskal-
Wallis rank test was performed to compare quantitative
data for the four treatment groups (parasitological clea-
rance and temperature resolution of fever), and the Wilcoxon
matched-pairs signed-ranks test was used to test the equality
of matched pairs of quantitative observations. P values
<0.05 were considered statistically significant.Ethical clearance
The protocol was reviewed and approved by the Scien-
tific Committee of the Faculty of Health Sciences of the
University of Bangue, CAR and authorized by the
Ministry of Health (No. 14/UB/FACSS/CSCVPER/09).
For all patients, written informed consent was provided
by a parent or guardian.Results
Baseline characteristics
The first patient was enrolled in May 2008, and the study
was completed in May 2009. The random assignment to
the four treatment groups of the 251 participants for
whom slide analysis showed the presence of P. falci-
parum is presented in Figure 1. Of the 251 participants,
226 completed the study (90%); 10% were lost to follow-
up, withdrew from the study or were withdrawn from the
per-protocol analysis. Demographic, parasitological and
clinical characteristics at baseline did not differ signifi-





















Table 1 Baseline characteristics of children at enrolment in a clinical trial of the efficacy of three artemisinin-containing
combinations therapies with amodiaquine + sulphadoxine–pyrimathamine (AQ-SP)
AS-SMP AS-AQ AL AQ-SP p
N = 58 N = 68 N = 60 N = 65
Age (months) 0.396
Median 43 34 40 36
Interquartile range 27-51 25-49 27-48 23-52
Minimum, maximum 7-59 7-59 3-58 2-59
Gender 0.235
Male (n (%)) 27 (47%) 39 (57%) 38 (63%) 32 (49%)
P. falciparum(/μl) 0.853
Median 17 000 18 509 16 471 14 400
Interquartile range 8200-60 000 6480-9 814 7200-58917 8000-36 000
Temperature at day 0 (°C) 0.198
Median 38,7 38.9 39.2 39.1
Interquartile range 38.3-39.7 38.3-39.9 38.4-40.2 38.4-39.7
AS-SMP, Artesunate + sulphamethoxypyrazine-pyrimethamine (Coarinate®); AS-AQ, Artesunate + amodiaquine (Coarsucam®); AL, Artemether + lumefantrine
(Coartem®); AQ + SP, Amodiaquine + sulphadoxine-pyrimethamine; N, Effective number.
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The day-28 PCR-corrected cure rates and their 95% CIs in
the per-protocol analysis ranged from 92% with AL to
100% with SP-AQ (Table 2), with no statistically signifi-
cant difference among the four treatments (p = 0.133). AsTable 2 Efficacy of three artemisinin-containing combinations
pyrimethamine (AQ-SP) on day 28 after PCR correction, per-pro




n % (95% CI) 1 2% (0–10) 0 0
LCF
n % (95% CI) 2 4% (0–13) 3 5
LPF
n % (95% CI) 1 2% (0–10) 1 2
ACPR
n % (95% CI) 50 93% (82–98) 55
Intention to treat analysis
(without PCR correction)
ETF
n % (95% CI) 1 2% (0–9) 0 0
LCF
n % (95% CI) 6 10% (4–21) 3 4
LPF
n % (95% CI) 1 2% (0–9) 1 1
ACPR
n % (95% CI) 48 83% (71–91) 55
AS-SMP, Artesunate + sulphamethoxypyrazine-pyrimethamine (Coarinate®); AS-AQ, A
(Coartem®); AQ + SP, Amodiaquine + sulphadoxine-pyrimethamine; N, Effective nexpected, the 28-day cure rates in the intention-to-treat
and in the PCR-uncorrected per-protocol analyses were
lower than those in the PCR-corrected per-protocol
analysis. On day 28, the PCR-corrected cure rates and
their 95% CIs in the intention-to-treat analysis were:therapy in comparison with amodiaquine + sulphadoxine–
tocol analysis
-AQ N = 59 AL N = 52 AQ-SP N = 57 p-value
% (0–6) 0 0% (0–7) 0 0% (0–6)
% (1–14) 2 4% (0–13) 0 0% (0–6)
% (0–9) 2 4% (0–13) 0 0% (0–6)
0.133
93% (84–98) 52 92% (81–98) 57 100% (94–100)
% (0–5) 0 0% (0–6) 0 0% (0–6)
% (1–12) 2 3%(0–12) 0 0% (0–6)
% (0–8) 3 5% (1–14) 1 2% (0–8)
81% (70–89) 48 80% (68–89) 57 88%(77–95) 0.058
rtesunate + amodiaquine (Coarsucam®); AL, Artemether + lumefantrine















Figure 3 Characteristics of patients during the first three days
after the start of treatment: median body temperature, p < 0.05.
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(77–95%) for the AL, AS-SMP, AS-AQ and SP-AQ groups,
respectively, with no significant difference among the
groups (p = 0.578). The day-28 PCR-uncorrected cure rates
in the per-protocol analysis also showed no significant
difference in efficacy (p = 0.077): 91% (79–97%), 86%
(74–94%), 93% (84–98%) and 98% (91–100%) for the
AL, AS-SMP, AS-AQ and SP-AQ groups, respectively.
Parasite clearance rates in each treatment group are pre-
sented in Figure 2. The prevalence of infection on day 3
after treatment was 2% (1/53), 2% (1/56), 0% (0/59), and
2% (1/58) in the AL, AS-SMP, AS-AQ and SP-AQ groups,
respectively; there was no statistically significant difference
among the groups on days 1, 2 and 3.
Resolution of fever was seen within three days in all treat-
ment groups, although the axillary temperature was always
lower after AS-AQ and higher after AL (Figure 3). The dif-
ference in fever clearance with the four treatments was
significant, with the lowest axillary temperature after AS-
AQ and the highest after AL on all three days. Indeed, the
mean body temperatures after AL, AS-SMP, AS-AQ and
SP-AQ were 37.6°C (37.4-37.8), 37.4°C (37.2-37.6), 37.2°C
(37.0-37.4) and 37.3°C (37.1-37.5) on day 1 (p = 0.017);
37.3°C (37.2-37.4), 37.2°C (37.1-37.3), 37.0°C (36.9-37.1)
and 37.1°C (36.9-37.2) on day 2 (p = 0.022); and 37.3°C
(37.2-37.5), 37.1°C (37.0-37.3), 37.0°C (36.9-37.1) and
37.5°C (37.0-37.7) on day 3 (p = 0.035).
Tolerability and safety
No deaths and no cases of severe malaria were seen du-
ring the study. All adverse events observed were mild
and consisted mainly of gastrointestinal symptoms
(vomiting, diarrhoea, abdominal pain and anorexia), fa-
tigue and pruritus (Table 3).
Fatigue was significantly more frequent in the two
groups of patients receiving AQ (9% with AS-AQ and
16% with SP-AQ; p = 0.006). Abdominal pain was also











Figure 2 Characteristics of patients during the first three days
after the start of treatment: proportion of patients with
parasites, p < 0.05.times more frequent in the groups receiving AS-SMP
(10%), AS-AQ (12%) and SP-AQ (12%) than in those
given AL (3%), but the differences were not statistically
significant. In the two groups receiving AQ, values more
than three times the normal were found for alanine ami-
notransferase on day 0 in one child and on day 1 in one
child (Figure 4) and for aspartate aminotransferase in six
children on day 1 and in three children on day 2 (Figure 5).
None of these abnormal biological values was clinically
significant. There was no statistically significant increase
in aminotransferase activity between day 0 and day 3
(Figures 4 and 5).
Discussion
This comparative evaluation of four treatments shows
satisfactory, comparable efficacy of AL, AS-SMP, AS-AQ
and SP-AQ. Only slight differences in cure rates and
parasite clearance rates were seen, which were not statis-
tically significant. Significant differences in defervescence
were found, AL being the less clinically efficient drug.
Thus, this study confirms the efficacy of ACT for the
treatment of uncomplicated malaria in children, as re-
ported previously [1,27,28]. As the study was designed
to demonstrate the superiority of ACT with respect to
SP-AQ, we did not investigate the non-inferiority of any
of the drugs.
No clinically significant hepatic toxicity, agranulocyto-
sis [29-32] or serious other side-effects were seen. No
significant increase in alanine or aspartate aminotransa-
minase activity was observed between day 0 and day 3.
AQ-containing combinations were associated with more
occurrences of fatigue than other drugs.
The finding that treatments containing SP or its deriva-
tive SMP (both drug are antifolates) did not increase cure
rates significantly in comparison with the other two com-
binations is puzzling, as resistance to SP in the CAR was
found to be high in vitro, i.e. up to 22.8% in 2004 [13,33]
and would not have diminished subsequently, as SP is still
commonly used, despite official recommendations.
Table 3 Frequency of mild-to-moderate adverse events on days 1–7 (related or not to treatment) with three
artemisinin-containing combinations therapies in comparison with amodiaquine + sulphadoxine–pyrimathamine
(AQ-SP)
AS-SMP AS-AQ AL AQ-SP p
N = 58 N = 68 N = 60 N = 65
At least one adverse event 24 35 17 32 0.037
% (95% CI) 41% (29–55) 51% (39–64) 28% (17–41) 49% (37–62)
Vomiting 10 12 4 12 0.177
Fever 11 14 8 6 0.143
Fatigue 4 9 3 16 0.006
Abdominal pain 3 8 2 9 0.112
Diarrhoea 4 6 4 5 0.976
Anorexia 3 4 3 8 0.377
Pruritus 2 4 0 4 0.222
Drowsiness 0 0 0 2 0.175
Aphthous stomatitis 0 1 0 1 1.000
Headache 1 0 1 0 0.359
Other* 6 7 3 6 0.666
AS-SMP, Artesunate + sulphamethoxypyrazine-pyrimethamine (Coarinate®); AS-AQ, Artesunate + amodiaquine (Coarsucam®); AL, Artemether + lumefantrine
(Coartem®); AQ + SP, Amodiaquine + sulphadoxine-pyrimethamine; N, Effective number; CI, Confidence interval. In bold: the only adverse event for which
statistically significant differences (p <0.01) are observed between the treatments.
*Intestinal, respiratory, skin infections, pain, anaemia, cough, injuries, skin rash.
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ample, in Rwanda [34] and the United Republic of
Tanzania [35], at least 25% resistance of P. falciparum to
SP was found, but assessment of the clinical efficacy of
combinations containing SP showed adequate clinical
and parasitological response rates of 90.3% [36] and 94%
[35] in the two countries, respectively. Similarly, AS-




































Figure 4 Concentrations of serum liver enzymes, expressed in multip
81 patients given amodiaquine treatments: results of alanine aminotrclinical and parasitological response rates (96.6%) in the
United Republic of Tanzania, Benin and Ghana [37,38].
Despite the high efficacy of AS-SMP and SP-AQ ob-
served in the present study, as in nearby countries, the
use of antifolates even in combination with ACT in en-
demic areas, where the rate of mutations associated with
resistance to this family of drugs (in dhfr or dhps) is
high, is not recommended [26]. The prevalence rate ofP=0.36
D1 D3







































Figure 5 Concentrations of serum liver enzymes, expressed in multiples of the upper limit of the normal range, on days 0, 1 and 3 in
81 patients given amodiaquine treatments: results of aspartate aminotransferase (AST).
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been also suggested that, in areas with high resistance to
pyrimethamine alone or with sulphadoxine, combina-
tions with AS might not be effective [39]. Artemisinin
derivatives should not be prescribed alone in order to
prevent the selection of resistance; therefore, in a sub-
sequent study molecular biology will be used to deter-
mine the prevalence of point mutations in the genes
Pfcrt, Pfmdr, Pfdhfr and Pfdhps, which are associated
with resistance to chloroquine, mefloquine, pyri-
methamine and sulphadoxine, respectively.
Conclusions
The efficacy of the three artemisinin-based combinations
evaluated did not differ significantly, and they were well
tolerated, although AL appeared to have a slight advan-
tage in terms of tolerability and to be associated with
slower defervescence. This finding should be confirmed
in a larger trial. Given the potential development of re-
sistance to SP and SMP and international recommenda-
tions, both AS-AQ and AL could be used in the CAR.
The results of this study should be taken into account
by the CAR National Malaria Control Programme in
recommending the most appropriate ACT for the country.
Further studies should be conducted to evaluate malaria
treatment and to reinforce good practice by medical staff.
Abbreviations
ACT: Artemisinin-based combination therapy; AL: Artemether–lumefantrine;
AQ: Amodiaquine; AS: Artesunate; CAR: Central African Republic;
CI: Confidence interval; PCR: Polymerase chain reaction;
SMP: Sulphamethoxypyrazine-pyrimethamine; SP: Sulphadoxine–pyrimethamine;
WHO: World Health Organization.
Competing interests
The authors declare that they have no competing interests.Authors’ contributions
All authors contributed to the design of the study or assisted with data
interpretation. DD coordinated the study and supervised the enrolment and
follow-up of patients. SPN enrolled patients. DD conducted molecular
analysis for determination of recrudescence or reinfection. DD, AM and
CR participated in analysing the data and writing the manuscript, and all
authors approved the final version.
Acknowledgements
We would like to acknowledge the study population for their kind
cooperation, as well as the laboratory technicians of the two health facilities
for participating in patient recruitment. Key persons involved in the study
were the physician at the Saint Joseph Health Centre, the laboratory staff at
the Paediatric Complex and the Saint Joseph Health Centre, and Mrs Ipéro
Julienne and Mr Mangonda Sosthène of the Institut Pasteur of Bangui.
The study was supported by the Institut Pasteur of Bangui. We thank the
following companies and organizations for donating antimalarial drugs:
Dafra Pharma, Sanofi-Adventis, Dr Dackpa Sébastien (Malaria Unit, United
Nations Development Programme) and the Unit for Provision of Drugs, CAR.
None of these organisations was involved in the study design, in the collection
of data, in the analysis or in preparation of the manuscript. Biological tests and
other costs were supported by the Institut Pasteur of Bangui.
Author details
1Institut Pasteur de Bangui, BP 923 Bangui, Central African Republic. 2Institut
de Recherche Biomédicale des Armées, Antenne de Marseille, Marseille,
France. 3Laboratoire de Virologie, Centre Hospitalier Universitaire de Nancy,
Hôpital de Brabois Adultes, 54511 Vandoeuvre-lès-Nancy, Cedex, France.
4Institut Pasteur de Madagascar, BP 1274, 101 Antananarivo, Madagascar.
Received: 7 August 2013 Accepted: 3 January 2014
Published: 7 January 2014
References
1. Sagara I, Rulisa S, Mbacham W, Adam I, Sissoko K, Maiga H, Traore OB, Dara
N, Dicko YT, Dicko A, Djimde A, Jansen FH, Doumbo OK: Efficacy and
safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine
compared to artemether-lumefantrine for the treatment of uncomplicated
falciparum malaria across Africa: a randomized multi-centre trial.
Malar J 2009, 8:63.
2. Gallup JL, Sachs JD: The economic burden of malaria. Am J Trop Med Hyg
2001, 64:85–96.
3. WHO: World Malaria Report. Geneva, Switzerland: WHO; 2005. WHO/HTM/
MAL/20051102 2005.
Djallé et al. Malaria Journal 2014, 13:9 Page 9 of 9
http://www.malariajournal.com/content/13/1/94. Greenwood BM, Bojang K, Whitty CJ, Targett GA: Malaria. Lancet 2005,
365:1487–1498.
5. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR:
Epidemiology of drug-resistant malaria. Lancet Infect Dis 2002, 2:209–218.
6. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI: The global distribution
of clinical episodes of Plasmodium falciparum malaria. Nature 2005,
434:214–217.
7. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F,
Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K,
Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N,
Socheat D, White NJ: Artemisinin resistance in Plasmodium falciparum
malaria. N Engl J Med 2009, 361:455–467.
8. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM: Evidence of
artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008,
359:2619–2620.
9. Adjuik M, Agnamey P, Babiker A, Borrmann S, Brasseur P, Cisse M, Cobelens
F, Diallo S, Faucher JF, Garner P, Gikunda S, Kremsner PG, Krishna S, Lell B,
Loolpapit M, Matsiegui PB, Missinou MA, Mwanza J, Ntoumi F, Olliaro P,
Osimbo P, rezbach P, Some E, Taylor WR: Amodiaquine-artesunate versus
amodiaquine for uncomplicated Plasmodium falciparum malaria in African
children: a randomised, multicentre trial. Lancet 2002, 359:1365–1372.
10. Falade C, Makanga M, Premji Z, Ortmann CE, Stockmeyer M, de Palacios PI:
Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-
dose regimen) in African infants and children with acute, uncomplicated
falciparum malaria. Trans R Soc Trop Med Hyg 2005, 99:459–467.
11. Omari AA, Gamble C, Garner P: Artemether-lumefantrine for
uncomplicated malaria: a systematic review. Trop Med Int Health 2004,
9:192–199.
12. Bharti C, Mukyaprana AS, Bairy KL: Evaluation of efficacy and toxicity of
different treatment regimens in Plasmodium falciparum. Asian J Pharm
Res Health Care 2009, 1:134–140.
13. Menard D, Madji N, Manirakiza A, Djalle D, Koula MR, Talarmin A:
Efficacy of chloroquine, amodiaquine, sulfadoxine-pyrimethamine,
chloroquine-sulfadoxine-pyrimethamine combination, and
amodiaquine-sulfadoxine-pyrimethamine combination in Central African
children with noncomplicated malaria. Am J Trop Med Hyg 2005,
72:581–585.
14. Programme National de Lutte contre le Paludisme: Directives nationales de
prise en charge des cas de paludisme. Bangui: Programme National de Lutte
contre le Paludisme; 2004.
15. Programme National de Lutte contre le Paludisme: Directives nationales de
prise en charge des cas de paludisme en République Centrafricaine. Bangui:
Programme National de lutte contre le Paludisme; 2006.
16. Manirakiza A, Njuimo SP, le Faou A, Malvy D, Millet P: Availability of
antimalarial drugs and evaluation of the attitude and practices for the
treatment of uncomplicated malaria in Bangui, Central African Republic.
East Afr J Public Health 2009, 6:292–295.
17. Menard D, Djalle D, Manirakiza A, Yapou F, Siadoua V, Sana S, Matsika-Claquin MD,
Nestor M, Talarmin A: Drug-resistant malaria in Bangui, Central African Republic:
an in vitro assessment. Am J Trop Med Hyg 2005, 73:239–243.
18. Ashley EA, Stepniewska K, Lindegardh N, Annerberg A, Kham A, Brockman
A, Singhasivanon P, White NJ, Nosten F: How much fat is necessary to
optimize lumefantrine oral bioavailability? Trop Med Int Health 2007,
12:195–200.
19. Ashley EA, Stepniewska K, Lindegardh N, McGready R, Annerberg A,
Hutagalung R, Singtoroj T, Hla G, Brockman A, Proux S, Wilahphaingern J,
White NJ, Nosten F: Pharmacokinetic study of artemether-lumefantrine
given once daily for the treatment of uncomplicated multidrug-resistant
falciparum malaria. Trop Med Int Health 2007, 12:201–208.
20. Nambei WS, Doui-Doumgba A, Bobossi G, Siadoua MD, Madji N, Folokete R,
Koula M, Garraud O: [Efficacy of artemether in the treatment of
uncomplicated Plasmodium falciparum malaria in children aged
6–60 months of age in Bangui (Central African Republic)]. Sante
2008, 18:49–53.
21. World Health Organization: Evaluation et surveillance de l’ efficacité des
antipaludiques pour le traitement du paludisme à Plasmodium falciparum non
compliqué (Rep. WHO/HTM/RBM/2003.50;2003). Geneva: World Health
Organization; 2003.
22. WHO: Severe falciparum malaria. World Health Organization,
Communicable Deseases Cluster. Trans R Soc Trop Med Hyg 2000, 37:105–125.23. Ezzet F, Mull R, Karbwang J: Population pharmacokinetics and therapeutic
response of CGP 56697 (artemether + benflumetol) in malaria patients.
Br J Clin Pharmacol 1998, 46:553–561.
24. White NJ, van Vugt M, Ezzet F: Clinical pharmacokinetics and
pharmacodynamics and pharmacodynamics of artemether-lumefantrine.
Clin Pharmacokinet 1999, 37:105–125.
25. WHO: Methods and techniques for Clinical Trial on Antimalarial Drug Efficacy:
genotyping to identify parasite populations. 29–31 May 2007. Amsterdam:
World Health Organization; 2008.
26. WHO: Guidelines for the Treatment of Malaria. 2nd edition. Geneva: World
Health Organization; 2010.
27. Adam I, Magzoub M, Osman ME, Khalil IF, Alifrangis M, Elmardi KA:
A fixed-dose 24-hour regimen of artesunate plus sulfamethoxypyrazine-
pyrimethamine for the treatment of uncomplicated Plasmodium falciparum
malaria in eastern Sudan. Ann Clin Microbiol Antimicrob 2006, 5:18.
28. Koram KAAB, Duah N, Quashie N: Comparative efficacy of antimalarial
drugs including ACTs in the treatment of uncomplicated malaria among
children under 5 years in Ghana. Acta Trop 2005, 95:194–203.
29. Bernuau J, Larrey D, Campillo B, Degott C, Verdier F, Rueff B, Pessayre D,
Benhamou JP: Amodiaquine-induced fulminant hepatitis. J Hepatol 1988,
6:109–112.
30. Larrey D, Castot A, Pessayre D, Merigot P, Machayekhy JP, Feldmann G,
Lenoir A, Rueff B, Benhamou JP: Amodiaquine-induced hepatitis. A report
of seven cases. Ann Intern Med 1986, 104:801–803.
31. Schulthess HK, von Felten A, Gmur J, Neftel K: [Amodiaquine-induced
agranulocytosis in malaria prevention: demonstration of an amodiaquine-
induced cytotoxic antibody against granulocytes](in German). Schweiz
Med Wochenschr 1983, 113:1912–1913.
32. Talani P, Samba G, Moyen G: [Management of child fever in the battle against
malaria in Brazzaville](in French). Bull Soc Pathol Exot 2002, 95:47–49.
33. Menard D, Djalle D, Yapou F, Manirakiza A, Talarmin A: Frequency
distribution of antimalarial drug-resistant alleles among isolates of
Plasmodium falciparum in Bangui, Central African Republic. Am J Trop
Med Hyg 2006, 74:205–210.
34. EANMAT: The efficacy of antimalarial monotherapies, sulphadoxine-
pyrimethamine and amodiaquine in East Africa: implications for
sub-regional policy. Trop Med Int Health 2003, 8:860–867.
35. Kabanywanyi AM, Mwita A, Sumari D, Mandike R, Mugittu K, Abdulla S:
Efficacy and safety of artemisinin-based antimalarial in the treatment of
uncomplicated malaria in children in southern Tanzania. Malar J 2007,
6:146.
36. Rulisa S, Gatarayiha JP, Kabarisa T, Ndayisaba G: Comparison of different
artemisinin-based combinations for the treatment of Plasmodium
falciparum malaria in children in Kigali, Rwanda, an area of resistance to
sulfadoxine-pyrimethamine: artesunate plus sulfadoxine/pyrimethamine
versus artesunate plus sulfamethoxypyrazine/pyrimethamine. Am J Trop
Med Hyg 2007, 77:612–616.
37. Mockenhaupt FP, Ehrhardt S, Dzisi SY, Teun Bousema J, Wassilew N, Schreiber J,
Anemana SD, Cramer JP, Otchwemah RN, Sauerwein RW, Egelte TA, Bienzle U:
A randomized, placebo-controlled, double-blind trial on sulfadoxine-
pyrimethamine alone or combined with artesunate or amodiaquine
in uncomplicated malaria. Trop Med Int Health 2005, 10:512–520.
38. Nahum A, Erhart A, Gazard D, Agbowai C, van Overmeir C, van Loen H,
Menten J, Akogbeto M, Coosemans M, Massougbodji A, D’Alessandro U:
Adding artesunate to sulphadoxine-pyrimethamine greatly improves the
treatment efficacy in children with uncomplicated falciparum malaria on
the coast of Benin, West Africa. Malar J 2007, 6:170.
39. Priotto G, Kabakyenga J, Pinoges L, Ruiz A, Eriksson T, Coussement F,
Ngambe T, Taylor WR, Perea W, Guthmann JP, Olliaro P, Legros D:
Artesunate and sulfadoxine-pyrimethamine combinations for the
treatment of uncomplicated Plasmodium falciparum malaria in
Uganda: a randomized, double-blind, placebo-controlled trial.
Trans R Soc Trop Med Hyg 2003, 97:325–330.
doi:10.1186/1475-2875-13-9
Cite this article as: Djallé et al.: Efficacy and safety of artemether +
lumefantrine, artesunate + sulphamethoxypyrazine-pyrimethamine and
artesunate + amodiaquine and sulphadoxine-pyrimethamine +
amodiaquine in the treatment of uncomplicated falciparum malaria in
Bangui, Central African Republic: a randomized trial. Malaria Journal
2014 13:9.
